Is Pimitespib a drug numbered NB003?
Pimitespib, also known as TAS-116, is a small molecule heat shock protein90 (HSP90) inhibitor, mainly used to treat gastrointestinal stromal tumors (GIST). By inhibiting the action of HSP90, it causes the instability of multiple key proteins in tumor cells, thereby inhibiting the growth and proliferation of tumor cells. Compared with traditional HSP90 inhibitors, pimetibib is less toxic to the retina and therefore may have a better safety profile during treatment.
Currently, pimetibib has not been approved for marketing in China, so Chinese patients cannot directly purchase the drug in domestic hospitals. However, patients can obtain the drug through overseas channels, such as cross-border e-commerce or overseas drug suppliers. Since medicines purchased through cross-border channels may face certain risks, including drug authenticity, transportation time, and tariffs, patients need to be particularly careful when purchasing.
In Japan, pimetibib (TAS-116) has been approved and marketed under the trade name "Jeselhy". The price of pimetibib in the Japanese market is relatively high, and the price of one box may reach more than 10,000 yuan. The price is a considerable burden for many patients. Despite this, due to the good efficacy of the drug, some patients still choose to purchase it through legal channels. In addition, generic versions of pimetibib are not yet on the market, but as the drug becomes more popular and market demand grows, more relatively inexpensive options may emerge in the future.
In general, Pimitespib (Pimitespib), as a targeted drug for gastrointestinal stromal tumors, has significant therapeutic effects. Although it is not currently available in the Chinese market, patients can still purchase it through overseas channels. However, when choosing a purchasing channel, patients need to pay special attention to the legality and safety of the channel, and use drugs under the guidance of a doctor.
Reference materials:https://www.mt-pharma.co.jp/e/company/rd/pipe/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)